Discovery of New Quinazoline-Based Anticancer Agents as VEGFR-2 Inhibitors and Apoptosis Inducers

Novel quinazoline compounds have been designed and synthesized aiming to discover new anticancer agents. Additional study was carried out on the most powerful derivatives, (Xb). A cell cycle research indicated that (Xb) mostly stops the cell cycle in the G2/M phase. The Annexin V-FITC apoptosis assay revealed that (Xb) increased apoptosis when compared with the control. It also demonstrated decreased anti-apoptotic Bcl-2 protein expression and increased BAX and caspases 3 expression levels.

Automated summary

This article investigates the activity of novel quinazoline compounds (Xb) designed and synthesized, focusing on their effects on cell cycle and apoptosis. The results show that (Xb) can stop cell cycle at G2/M phase and induce apoptosis. This effect may be achieved by downregulating the expression of anti-apoptotic protein Bcl-2 and upregulating the expression levels of BAX and caspases 3.